Objective: Smooth muscle cell (SMC) migration from the media into the intima is pivotal for intimal formation after vascular injury. Platelet-derived growth factor (PDGF)-BB is a potent chemoattractant for SMCs in vitro and in vivo. We investigated whether interleukin (IL)-1␤ affects migration in response to PDGF-BB. Our data suggest that IL-1␤ is inhibitory and that this effect is mediated by cyclooxygenase (COX)-2. We further addressed the role of the mitogenactivated protein kinase p38, which is activated by PDGF-BB and by IL-1␤. Methods: Baboon aortic SMCs were prepared with the explant method. Migration was measured in a Boyden chamber assay through filters coated with monomeric collagen. COX2 expression and phosphorylation of p38 MAPK were analyzed by Western blotting. Results: PDGF-BB (10 ng/mL) stimulates migration 3.8-fold, and IL-1␤ (0.1 ng/mL) reduces this response by 40%. The inhibitory effect of IL-1␤ is abolished by the COX inhibitor, indomethacin (10 mol/L), the specific COX2 inhibitor, NS398 (10 mol/L), and the p38 MAPK inhibitor SB203580 (3 mol/L). We found that IL-1␤ and PDGF-BB synergize to stimulate COX2 expression. We further demonstrated that p38 MAPK is activated by IL-1␤ and PDGF with different kinetics and that p38 MAPK is required for maximal COX2 expression in response to IL-1␤ plus PDGF-BB.
Recurrent stenosis is a serious complication of arterial repair, and is caused by pathologic vessel remodeling and intimal hyperplasia. Platelet deposition and degranulation after arterial injury is a crucial process for neointimal growth, 1 and platelet-derived growth factor (PDGF) is the major platelet-derived chemoattractant and mitogen for smooth muscle cells (SMCs). The importance of PDGF in intimal growth has been demonstrated in various animal models, including baboons. 2, 3 The principal effect of PDGF appears to be stimulation of SMC migration, [2] [3] [4] [5] [6] although stimulation of SMC proliferation has also been suggested. 7, 8 PDGF effects in the response to vascular injury appear to be mainly mediated by PDGF receptor beta. For example, blockade of PDGF-receptor beta, but not alpha, inhibits intimal hyperplasia in the balloon-injured baboon carotid artery. 2 There are multiple lines of evidence that inflammatory processes contribute to recurrent stenosis after vascular injury. 9 Proinflammatory cytokines such as interleukin (IL)-1 are potentially attractive targets to suppress intimal hyperplasia, because they are unlikely to control normal vessel functions. A role for IL-1 in recurrent stenosis has been proposed. 10 In human beings a polymorphism in the IL receptor antagonist (IL-RA) locus has been discovered, which may protect from recurrent stenosis after coronary angioplasty 11 and after coronary stenting. 12 Although the consequences of this polymorphism for IL-RA expression in the vessel wall are not known, observations in IL-RAdeficient mice point to an anti-inflammatory function of IL-RA in arteries. 13 Animal models in which IL-1 has been investigated include pigs and mice. Chronic stimulation of healthy pig coronary arteries with IL-1 produces intimal lesions.
14 In IL-1R1-deficient mice, compared with wildtype animals, intimal hyperplasia is reduced after carotid artery ligation. 15 After balloon injury, expression of IL-1 is induced in the rat carotid artery 16 and pig coronary artery. 17 Multiple mechanisms may contribute to stimulation of intimal hyperplasia by IL-1, including direct activation of SMC proliferation.
Because PDGF and IL-1␤ are generated concomitantly at vascular injury, we investigated whether both factors cooperate to stimulate SMC functions. We recently reported that IL-1␤ potentiates PDGF-BB-induced proliferation. A likely mechanism is that IL-1␤ suppresses induction of cell cycle inhibitors p21 (WAF1/CIP1) and p27 (KIP1), thereby enhancing cyclin-dependent kinase 2 activation and proliferation. 18 Here we investigated the effects of IL-1␤ on PDGF-BB-induced migration. We found that IL-1␤ is inhibitory and that this effect relies on synergistic expression of cyclooxygenase (COX)-2 by IL-1␤ and PDGF-BB.
METHODS
Material. IL-1␤ was obtained from R & D Systems (Minneapolis, Minn). PDGF-BB was generously provided by Zymogenetics (Seattle, Wash). Indomethacin, NS398, and SB203580 were purchased from Calbiochem (La Jolla, Calif). Antibodies against COX2 and phospho-p38 MAPK were from Cayman (Ann Arbor, Mich) and Cell Signaling Technology (Beverly, Mass), respectively. All tissue culture solutions were from Gibco/Invitrogen Life Technologies (Carlsbad, Calif).
Cell culture. Baboon and human aortic SMCs were prepared with the explant method. 19 Aortic SMCs from FVB mice were a kind gift from Michael Reidy (University of Washington, Seattle). All cells were grown in Dulbecco modified Eagle medium high glucose supplemented with 10% fetal bovine serum, 200 U/mL of penicillin, and 0.2 mg/mL of streptomycin. SMCs between 5 and 12 passages were used. To achieve quiescence, growth medium was removed and cells were incubated for 1 to 3 days in MCDB131 supplemented with antibiotics and 2 mmol/L of glutamine.
Western blot analysis. Quiescent SMCs were stimulated with 10 ng/mL of PDGF-BB with or without 0.1 ng/mL of IL-1␤. Where indicated, SB203580 was added 30 minutes before stimulation. At the time points indicated, cells were washed twice in phosphate-buffered saline solution and lysed in Laemmli buffer containing 2% sodium dodecylsulfate. Lysates were boiled, and subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis (10-30 g of protein per lane) followed by Western blotting. Blots were blocked with 5% skim milk in Tris-Tweenbuffered saline solution (25 mmol/L of Tris hydrochloride [pH 7.5], 150 mmol/L of sodium chloride, 0.1% Tween-20) for 1 hour at room temperature, and incubated at 4°C overnight with primary antibody (0.1-0.5 g/mL). Protein bands were visualized with enhanced chemiluminescence, according to the manufacturer's protocol (Amersham/Pharmacia, Piscataway, NJ). For semiquantitative analysis, films were scanned and band intensity was determined with Image Quant software (Molecular Dynamics/Amersham).
Boyden chamber assay. Boyden chamber assays were performed in a 48-well microchemotaxis chamber (Neuro Probe, Gaithersburg, Md) with vitrogen-coated (Collagen Corp, Palo Alto, Calif) polycarbonate filters (pore size, 10 m; Neuropore Corp, Pleasanton, Calif), as described. 20 In brief, SMCs were grown in 10% fetal bovine serum to near confluency, harvested, and counted. Cells (35,000 per well) were placed in the upper chamber, and the lower chamber contained the chemoattractant. Where indicated, IL-1␤ was added to cells 2 hours before harvest. Inhibitors were added 30 minutes before IL-1␤. Inhibitors and IL-1␤ were then added back into the upper chamber. The chamber was kept for 5 hours at 37°C in a humidified incubator at 5% carbon dioxide. Cells on the bottom of the filters were fixed with methanol and stained with Diff-Quick staining solution (Baxter, Deerfield, Ill). Migration was measured as the number of cells per high-power field (100ϫ) that migrated across the membrane between the upper and lower chambers.
Statistical analysis. All experiments were performed at least three times. Where indicated, statistical significance between control and experimental groups was calculated with adjusted Bonferroni comparisons 21 or paired Student t test. Differences at P Ͻ .05 were considered significant.
RESULTS

IL-1␤ inhibits PDGF-BB-induced migration in a COX2 and p38 mitogen-activated protein kinase (MAPK)-dependent manner.
In a Boyden chamber assay, PDGF-BB (10 ng/mL) typically stimulates SMC migration by three to four times. This response is inhibited by 40% when IL-1␤ (0.1 ng/mL) is added (Fig 1) . Doses of PDGF-BB and IL-1␤ used have been recently established as optimal in these cells for IL-1␤ and PDGF-BB with respect to growth stimulatory effects of IL-1␤ on PDGF-BB-induced proliferation. 18 To test the possibility that COX2 mediates the inhibitory effect of IL-1␤, we used the general COX inhibitor indomethacin (10 mol/L) and the COX2 specific inhibitor NS398 (10 mol/L). Given previous observations that p38 MAPK is critical for COX2 expression by IL-1␤ in airway SMCs, 22 we also investigated the effect of the p38 MAPK inhibitor SB203580 (3-10 mol/L). Indomethacin (Fig 1, A) and SB203580 (Fig 1,  C ) have no effect on PDGF-BB-induced migration, whereas NS398 may be slightly inhibitory (Fig 1, B) . The migratory response to PDGF-BB in the presence of either compound (indomethacin, NS-398, SB203580) was higher than the response to PDGF-BB in the presence of IL-1␤ (Fig 1) . Addition of either drug significantly stimulates migration by IL-1␤ plus PDGF-BB (Fig 1) . Together these data indicate thet IL-1␤ inhibits PDGF-BB-induced migration in a mechanism that depends on COX2 and p38 MAPK.
IL-1␤ synergizes with PDGF-BB to stimulate COX2 expression; role of p38 MAPK. To investigate COX2 expression, we determined COX2 protein levels with Western blotting after 5-hour stimulation with PDGF-BB in the absence or presence of IL-1␤. The 5-hour time point was chosen because Boyden chambers were also incubated for 5 hours after PDGF-BB stimulation. IL-1␤ (0.1 ng/mL) alone induces COX2 expression twofold over untreated controls, whereas PDGF-BB has no significant effect. COX2 expression markedly increases in cells on costimulation with IL-1␤ and PDGF-BB (Fig 2) . Because such synergism has not yet been reported, we addressed the question of whether it is specific for baboon SMCs or is of more general validity. We found synergistic expression of COX2 by PDGF-BB and IL-1␤ in murine and human SMCs (Fig 3) .
To demonstrate that p38 MAPK is involved in COX2 expression by IL-1␤ and PDGF-BB, we measured COX2 in SMCs treated with SB203580. The inhibitor blocks expression of COX2 under all conditions. Significant is an inhibition of 50% after stimulation with IL-1␤ plus PDGF-BB (Fig 2) . We next examined the extent to which IL-1␤ and PDGF-BB contribute to p38 MAPK activation. Activity of p38 MAPK was determined by assessing its phosphorylation status with a phospho-specific antibody. Both factors transiently stimulate p38 MAPK, but the kinetics is different. PDGF-BB activation of p38 MAPK peaks at 10 minutes, whereas p38 MAPK activation by IL-1␤ is maximal at 30 minutes (Fig 4) . Costimulation of SMCs with IL-1␤ plus PDGF-BB results in higher p38 MAPK activity at each time point when compared with cells stimulated with either factor alone (Fig 4) . After 60 minutes p38 MAPK phosphorylation is absent, regardless of stimulants used (Fig 4; data for 3-hour, 4-hour, and 5-hour time points not shown). Interleukin-1␤ (IL-1␤) inhibits platelet-derived growth factor-BB-induced migration in a mechanism dependent on cyclooxygenase-2 and p38 mitogen-activated protein kinase. Where indicated, smooth muscle cells were preincubated for 30 minutes with 10 mol/L of indomethacin (A), 10 mol/L of NS398 (B), or 3 mol/L of SB203589 (C) before addition of IL-1␤ (0.1 ng/mL) for 2 hours. Cells were harvested and subjected to Boyden chamber assay with PDGF-BB (10 ng/mL) as stimulant (see Methods). Data (mean Ϯ SD) are presented as percent activity, with 100% for unstimulated controls (n ϭ 3 for each group). Statistical significance for the indicated pairwise comparisons was calculated with adjusted Bonferroni correction. All comparisons are significant at P Ͻ .05. 
DISCUSSION
Both IL-1␤ [22] [23] [24] [25] and PDGF 26 have been described as stimulating COX2 expression in SMCs. What has not yet been appreciated is that both factors strongly cooperate to induce COX2. This mechanism is present in human, baboon, and murine SMCs, whereas the potency of PDGF-BB or IL-1␤ alone to stimulate COX2 expression may vary between species (Figs 2 and 3) . The reason for this apparent difference between species is not known. One major consequence of the synergistic expression of COX2 by IL-1␤ and PDGF-BB is an inhibition of PDGF-BBinduced migration (Fig 1) . The molecular basis for the synergism between PDGF-BB and IL-1␤ in expressing COX2 remains to be elucidated. Our data suggest that p38 MAPK, which is activated by both factors, with differing kinetics (Fig 4) , has a crucial role in maximal COX2 expression in response to IL-1␤ plus PDGF-BB. Blockade of p38 MAPK decreases COX2 expression to an extent that the enzyme no longer inhibits PDGF-BB-induced migration (Figs 1,C and 2) . Given recent findings in other cell types, [27] [28] [29] it is likely that p38 MAPK is required for message stabilization. Blockade of p38 MAPK does not abolish COX2 expression by PDGF-BB plus IL-1␤, suggesting additional cooperation of the two factors at the transcription level. Our observation that PDGF-BB and IL-1␤ stimulate p38 MAPK with different kinetics may indicate that both factors use different signaling pathways for p38 MAPK activation.
The role of COX2 in recurrent stenosis remains to be clarified. COX2 is expressed at arterial injury, but blockade of COX2 in the balloon-injured rat carotid artery had no effect on lesion development. 30 It is likely that consequences of COX2 expression in the developing intima are complex, and have positive and negative influence on neointimal formation. COX2-mediated synthesis of inflammatory prostaglandins may promote intimal growth by stimulating recruitment of macrophages, which in turn release SMC mitogens and chemoattractants. In addition, prostaglandins may stimulate the growth of new blood vessels, which supply the growing intima. On the other hand, prostaglandin E 2 and prostacyclin both stimulate cyclic adenosine monophosphate production in SMCs, which inhibits proliferation. Consistent with this mechanism are recent observations in prostacyclin receptor-deficient mice, in which injury-induced vascular proliferation and platelet activation are enhanced, compared with in controls. 31 Our observation that IL-1␤ inhibits SMC migration suggests that IL-1␤ may attenuate intimal formation at early stages after injury. We have recently reported that IL-1␤ potentiates PDGF-BB-induced growth by inhibiting expression of cell cycle-dependent kinase inhibitors p21 and p27. It may be speculated that the immediate release of IL-1␤ after injury restricts intimal formation by inhibiting SMC migration, but when present over the long term IL-1␤ promotes intimal growth by stimulation of intimal SMC proliferation.
